Chughtai B, et al. - Researchers presented short-term safety and effectiveness data of men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) treated with Aquablation. From February 2016 to December 2017, men with LUTs secondary to BPH (60–150 cc) underwent Aquablation treatment across 17 investigational sites in the USA from two contemporary investigational device exemption (IDE) studies called WATER and WATER II. For this analysis, 107 males with mean age of 67.3 ± 6.5 years were treated with Aquablation. In a pooled analysis, men with LUTS secondary to BPH (60–150 cc) were treated harmlessly and effectively with Aquablation up to 3 months postoperatively.